Huang Haiying, Sakurai Fuminori, Higuchi Yuriko, Kawakami Shigeru, Hashida Mitsuru, Kawabata Kenji, Mizuguchi Hiroyuki
Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, Ibaraki, Osaka, Japan.
J Control Release. 2009 Jan 19;133(2):139-45. doi: 10.1016/j.jconrel.2008.09.081. Epub 2008 Oct 7.
To date, no countermeasures have been developed to overcome adenovirus (Ad) vector-induced innate immune responses in gene therapies that utilize these vectors. In the present study, we attempted to suppress Ad vector-induced innate immune responses and hepatotoxicity by delivering an NF-kappaB decoy to splenic macrophages and dendritic cells, as well as to Kupffer cells in the liver, using sugar-modified cationic liposomes. Pre-injection of the sugar-modified cationic liposome/NF-kappaB decoy complexes reduced serum levels of interleukin (IL)-12, which is a typical inflammatory cytokine induced by Ad vectors, and also reduced hepatotoxicity following Ad vector injection. Electrophoretic mobility shift assay demonstrated a reduction of Ad vector-induced NF-kappaB activation by pre-injection of the sugar-modified cationic liposome/NF-kappaB decoy complexes. Two types of sugar-modified cationic liposomes, fucosylated cationic liposomes (Fuc-liposomes) and mannosylated cationic liposomes (Man-liposomes), were tested in this study. Man-liposomes, which are considered to have greater affinity than Fuc-liposomes for splenocytes, appeared to have superior suppressive effects to those of Fuc-liposomes. Pre-injection of the sugar-modified cationic liposome/NF-kappaB decoy complexes did not inhibit Ad vector-mediated transduction in the organs. This study provides important findings for overcoming Ad vector-induced innate immune responses.
迄今为止,在利用腺病毒(Ad)载体的基因治疗中,尚未开发出克服Ad载体诱导的先天免疫反应的对策。在本研究中,我们试图通过使用糖修饰的阳离子脂质体将NF-κB诱饵递送至脾巨噬细胞、树突状细胞以及肝脏中的库普弗细胞,来抑制Ad载体诱导的先天免疫反应和肝毒性。预先注射糖修饰的阳离子脂质体/NF-κB诱饵复合物可降低血清白细胞介素(IL)-12水平,IL-12是Ad载体诱导的典型炎性细胞因子,同时也可降低Ad载体注射后的肝毒性。电泳迁移率变动分析表明,预先注射糖修饰的阳离子脂质体/NF-κB诱饵复合物可降低Ad载体诱导的NF-κB激活。本研究测试了两种糖修饰的阳离子脂质体,岩藻糖基化阳离子脂质体(Fuc-脂质体)和甘露糖基化阳离子脂质体(Man-脂质体)。Man-脂质体被认为对脾细胞的亲和力比Fuc-脂质体更高,其抑制作用似乎优于Fuc-脂质体。预先注射糖修饰的阳离子脂质体/NF-κB诱饵复合物并未抑制Ad载体介导的器官转导。本研究为克服Ad载体诱导的先天免疫反应提供了重要发现。